news
New CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
List view / Grid view
Cancer research
news
USC partners with Autobahn Labs to accelerate drug discovery
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
article
Biotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
news
INPP4B exerts its tumour-promoting effects via lysosomes
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
news
Computational pipeline for personalised cancer vaccine design
16 October 2024 | By
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
news
How chronic stress hastens the progression of colorectal cancer
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
news
Developing the world’s first ovarian cancer prevention vaccine
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
news
KRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
news
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
news
Anti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
news
Largest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
news
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
news
BCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
